

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 06 October 2025

FOI Ref 30569

Requested Information:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
- Atezolizumab
- Capivasertib
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Elacestrant
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab Monotherapy
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Carboplatin + Paclitaxel + Pembrolizumab
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab emtansine (Kadcyla)
- Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)			
Pertuzumab (Perteja) + Trastuzumab (Herceptin)			
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel			
Trastuzumab deruxtecan (Enhertu)			
Trastuzumab emtansine (Kadcyla)			
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Abemaciclib + Fulvestrant			
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Ribociclib + Fulvestrant			
Capecitabine as a single agent			
Carboplatin + Paclitaxel			
Carboplatin + Paclitaxel + Pembrolizumab			

Q3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Response:

Data from June to August 2025

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **35**
- Abemaciclib + Fulvestrant **1**
- Alpelisib + Fulvestrant **0**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only **22**

- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel **0**
- Atezolizumab **2**
- Capivasertib **4** (all 4 patients also received Fulvestrant)
- Capecitabine as a single agent **15**
- Carboplatin + Paclitaxel **5**
- Elacestrant **8** (1 of these also received Palbociclib)
- Eribulin as a single agent or in combination **5**
- Everolimus + Exemestane **1**
- Fulvestrant as a single agent **7**
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **57**
- Palbociclib + Fulvestrant **15**
- Parp Inhibitors (Olaparib/Talazoparib) **1**
- Pembrolizumab Monotherapy **12**
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide **10**
- Carboplatin + Paclitaxel + Pembrolizumab **0**
- Pertuzumab (Perteja) + Trastuzumab (Herceptin) **1**
- Phesgo (Pertuzumab + Trastuzumab in a single injection) **57**
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **44**
- Ribociclib + Fulvestrant **13**
- Sacituzumab Govitecan **4**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent **13**
- Trastuzumab deruxtecan (Enhertu) **8**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **23**
- Trastuzumab emtansine (Kadcyla) **5**
- Any other active systemic anti-cancer therapy:
 - Aromatase Inhibitor only **80**
 - Carboplatin **3**
 - Denosumab **33**

Q2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	57	26	31
Pertuzumab (Perteja) + Trastuzumab (Herceptin)	1	0	1

Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	23	15	8
Trastuzumab deruxtecan (Enhertu)	8	0	8
Trastuzumab emtansine (Kadcyla)	5	3	2
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	35	31	4
Abemaciclib + Fulvestrant	1	0	1
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	44	1	43
Ribociclib + Fulvestrant	13	0	13
Capecitabine as a single agent	16	1	15
Carboplatin + Paclitaxel	5	4	1
Carboplatin + Paclitaxel + Pembrolizumab	0	0	0

Q3. Does your trust participate in any clinical trials for breast cancer? **Yes** If so, please provide the name of each trial, and the number of patients taking part.

BNT323-01 - no patients currently enrolled

Elegant x - 2 patients

TRAK-ER - 2 patients

Fourlight-3 - 1 patient

Izabright Breast 01 - no patients currently enrolled

Evopar Breast - no patients currently enrolled

Kortuc - 1 patient

MK2870-012 - no patients currently enrolled

MK2870-010 - 1 patient

Attachment(s):

No Attachment(s)

Date Response sent: 15th October 2025